AAAAAA
Results: 1-25/57
Authors:
Shimoni, A
Gajewski, J
Donato, M
Martin, T
O'Brien, S
Talpaz, M
Cohen, A
Korbling, M
Champlin, R
Giralt, S
Citation: A. Shimoni et al., Long-term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation, BIOL BLOOD, 7(10), 2001, pp. 568-575
Authors:
Giles, FJ
Kantarjian, H
O'Brien, S
Rios, MB
Cortes, J
Beran, M
Koller, C
Keating, M
Talpaz, M
Citation: Fj. Giles et al., Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with Philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase, LEUK LYMPH, 41(3-4), 2001, pp. 309-319
Authors:
Gordon, MS
Margolin, K
Talpaz, M
Sledge, GW
Holmgren, E
Benjamin, R
Stalter, S
Shak, S
Adelman, DC
Citation: Ms. Gordon et al., Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer, J CL ONCOL, 19(3), 2001, pp. 843-850
Authors:
Kurzrock, R
Cortes, J
Thomas, DA
Jeha, S
Pilat, S
Talpaz, M
Citation: R. Kurzrock et al., Pilot study of low-dose interleukin-11 in patients with bone marrow failure, J CL ONCOL, 19(21), 2001, pp. 4165-4172
Authors:
Kurzrock, R
Bueso-Ramos, CE
Kantarjian, H
Freireich, E
Tucker, SL
Siciliano, M
Pilat, S
Talpaz, M
Citation: R. Kurzrock et al., BCR rearrangement-negative chronic myelogenous leukemia revisited, J CL ONCOL, 19(11), 2001, pp. 2915-2926
Authors:
Kalidas, MT
Kantarjian, H
Talpaz, M
Citation: Mt. Kalidas et al., Chronic myelogenous leukemia, J AM MED A, 286(8), 2001, pp. 895-898
Authors:
Talpaz, M
Citation: M. Talpaz, Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition, SEM HEMATOL, 38(3), 2001, pp. 22-27
Authors:
Druker, BJ
Talpaz, M
Resta, DJ
Peng, B
Buchdunger, E
Ford, JM
Lydon, NB
Kantarjian, H
Capdeville, R
Ohno-Jones, S
Sawyers, CL
Citation: Bj. Druker et al., Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinasein chronic myeloid leukemia., N ENG J MED, 344(14), 2001, pp. 1031-1037
Authors:
Druker, BJ
Sawyers, CL
Kantarjian, H
Resta, DJ
Reese, SF
Ford, JM
Capdeville, R
Talpaz, M
Citation: Bj. Druker et al., Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia withthe philadelphia chromosome., N ENG J MED, 344(14), 2001, pp. 1038-1042
Authors:
Laurent, E
Talpaz, M
Kantarjian, H
Kurzrock, R
Citation: E. Laurent et al., The BCR gene and Philadelphia chromosome-positive leukemogenesis, CANCER RES, 61(6), 2001, pp. 2343-2355
Authors:
Wang, Y
Liu, JX
Wu, Y
Luo, WP
Lin, SH
Lin, H
Hawk, N
Sun, T
Guo, JQ
Estrov, Z
Talpaz, M
Champlin, R
Arlinghaus, RB
Citation: Y. Wang et al., Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death, CANCER RES, 61(1), 2001, pp. 138-144
Authors:
Kantarjian, HM
Talpaz, M
Santini, V
Murgo, A
Cheson, B
O'Brien, SM
Citation: Hm. Kantarjian et al., Homoharringtonine - History, current research, and future directions, CANCER, 92(6), 2001, pp. 1591-1605
Authors:
Kantarjian, HM
Shan, JQ
Smith, T
Talpaz, M
Kozuch, P
Rios, MB
Cortes, J
Giles, FJ
O'Brien, S
Citation: Hm. Kantarjian et al., Response to therapy is independently associated with survival prolongationin chronic myelogenous leukemia in the blastic phase, CANCER, 92(10), 2001, pp. 2501-2507
Authors:
Ravandi, F
Hayes, K
Cortes, J
Albitar, M
Glassman, A
Talpaz, M
Kantarjian, HM
Citation: F. Ravandi et al., Translocation t(17;18)(q10;q10) - A new nonrandom chromosomal translocation of clonal evolution in chronic myeloid leukemia, CANCER, 91(9), 2001, pp. 1704-1708
Authors:
Ravandi, F
Kantarjian, HM
Talpaz, M
O'Brien, S
Faderl, S
Giles, FJ
Thomas, D
Cortes, J
Andreeff, M
Estrov, Z
Rios, MB
Albitar, M
Citation: F. Ravandi et al., Expression of apoptosis proteins in chronic myelogenous leukemia - Associations and significance, CANCER, 91(11), 2001, pp. 1964-1972
Authors:
Talpaz, M
O'Brien, S
Rose, E
Gupta, S
Shan, JQ
Cortes, J
Giles, FJ
Faderl, S
Kantarjian, HM
Citation: M. Talpaz et al., Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia, BLOOD, 98(6), 2001, pp. 1708-1713
Authors:
Kardinal, C
Konkol, B
Lin, H
Eulitz, M
Schmidt, EK
Estrov, Z
Talpaz, M
Arlinghaus, RB
Feller, SM
Citation: C. Kardinal et al., Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes, BLOOD, 98(6), 2001, pp. 1773-1781
Authors:
Gisslinger, H
Kurzrock, R
Gisslinger, B
Jiang, SW
Li, SR
Virgolini, I
Woloszczuk, W
Andreeff, M
Talpaz, M
Citation: H. Gisslinger et al., Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon alpha: involvement of tumor necrosis factor as ligand for the CD95 receptor, BLOOD, 97(9), 2001, pp. 2791-2797
Authors:
Donato, NJ
Wu, JY
Zhang, L
Kantarjian, H
Talpaz, M
Citation: Nj. Donato et al., Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulatingfactor receptor beta-chain in BCR-ABL(+) human leukemic cells: associationwith loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition, BLOOD, 97(9), 2001, pp. 2846-2853
Authors:
Donato, NJ
Talpaz, M
Citation: Nj. Donato et M. Talpaz, Clinical use of tyrosine kinase inhibitors: Therapy for chronic myelogenous leukemia and other cancers, CLIN CANC R, 6(8), 2000, pp. 2965-2966
Authors:
Reuben, JM
Lee, BN
Johnson, H
Fritsche, H
Kantarjian, HM
Talpaz, M
Citation: Jm. Reuben et al., Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha, CLIN CANC R, 6(5), 2000, pp. 1671-1677
Authors:
Rodriguez, J
Cortes, J
Talpaz, M
O'Brien, S
Smith, TL
Rios, MB
Kantarjian, H
Citation: J. Rodriguez et al., Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia, CLIN CANC R, 6(1), 2000, pp. 147-152
Authors:
Tannir, NM
Talpaz, M
Ghazal, H
Proothi, S
Kantarjian, HM
Citation: Nm. Tannir et al., Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia, LEUK LYMPH, 39(5-6), 2000, pp. 647-650
Authors:
Faderl, S
Kantarjian, HM
Talpaz, M
Estrov, Z
Citation: S. Faderl et al., Clinical significance of minimal residual disease in leukemia (Review), INT J ONCOL, 17(6), 2000, pp. 1277-1287
Authors:
Kardinal, C
Konkol, B
Schulz, A
Posern, G
Lin, H
Adermann, K
Eulitz, M
Estrov, Z
Talpaz, M
Arlinghaus, RB
Feller, SM
Citation: C. Kardinal et al., Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients, FASEB J, 14(11), 2000, pp. 1529-1538